Skip to main content

Durham drugmaker recaptures pre-Covid momentum for glaucoma treatment

The company's year-over-year revenue was up 13 percent for the first quarter.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.